Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50902 |
Name | medulloblastoma |
Definition | An infratentorial cancer that is located_in the lower part of the brain and is a type of primitive neuroectodermal tumor. |
Source | DiseaseOntology.org |
Alt Ids | DOID:4981 DOID:168 DOID:0060105 DOID:3858 |
Path | disease disease of cellular proliferation cancer organ system cancer nervous system cancer central nervous system cancer brain cancer infratentorial cancer medulloblastoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
TP53 mutant | JQ1 | medulloblastoma | decreased response | detail... |
TP53 wild-type | JQ1 | medulloblastoma | sensitive | detail... |
RB1 positive | Palbociclib | medulloblastoma | sensitive | detail... |
CTNNB1 mutant | N/A | medulloblastoma | not applicable | detail... |
APC mutant | N/A | medulloblastoma | not applicable | detail... |
TP53 mutant | N/A | medulloblastoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00089245 | Phase I | Omburtamab I-131 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer | Terminated | USA | 0 |
NCT00601003 | Phase II | Cyclophosphamide + Nifurtimox + Topotecan | Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma | Completed | USA | 0 |
NCT00602667 | Phase I | Cisplatin + Cyclophosphamide + Methotrexate + Vincristine Sulfate Cyclophosphamide + Etoposide + Topotecan Cyclophosphamide + Erlotinib + Topotecan | Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma | Active, not recruiting | USA | AUS | 0 |
NCT00876993 | Phase I | Bevacizumab + Irinotecan + Temozolomide | Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors | Completed | USA | 0 |
NCT00983398 | Phase Ib/II | Pegfilgrastim Filgrastim Carboplatin + Melphalan | Melphalan, Carboplatin, and Sodium Thiosulfate for Patients With Central Nervous System (CNS) Embryonal or Germ Cell Tumors | Unknown status | USA | 0 |
NCT01217437 | Phase II | Irinotecan + Temozolomide Bevacizumab + Irinotecan + Temozolomide | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | Completed | USA | NZL | CAN | AUS | 1 |
NCT01331135 | Phase I | Sirolimus | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors | Completed | USA | 0 |
NCT01356290 | Phase II | Thalidomide Fenofibrate Etoposide Bevacizumab Celecoxib Cyclophosphamide + Cytarabine | Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma (MEMMAT) | Recruiting | USA | SWE | NOR | FRA | ESP | DNK | AUT | 1 |
NCT01878617 | Phase II | Vismodegib Cisplatin + Cyclophosphamide + Vincristine Sulfate Gemcitabine + Pemetrexed Disodium | A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma | Active, not recruiting | USA | NZL | CAN | AUS | 0 |
NCT01977677 | Phase Ib/II | Temozolomide Plerixafor | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | Completed | USA | 0 |
NCT01999270 | Phase I | Bevacizumab + Irinotecan | Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors | Completed | USA | 0 |
NCT02040376 | Phase III | Metformin | Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma | Completed | CAN | 0 |
NCT02100891 | Phase II | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors | Completed | USA | 0 | |
NCT02301039 | Phase II | Pembrolizumab | A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas | Completed | USA | 0 |
NCT02304458 | Phase Ib/II | Ipilimumab + Nivolumab | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | Completed | USA | CAN | 0 |
NCT02332889 | Phase Ib/II | Decitabine Poly ICLC | Phase I/II Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs | Terminated | USA | 0 |
NCT02372006 | Phase Ib/II | Afatinib | Trial of Afatinib in Pediatric Tumours | Completed | USA | NLD | ITA | GBR | FRA | ESP | DNK | DEU | CAN | AUT | AUS | 1 |
NCT02390752 | Phase Ib/II | Pexidartinib | PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) | Recruiting | USA | 0 |
NCT02446431 | Phase I | Cyclophosphamide Bevacizumab Temsirolimus Valproic acid | Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | Recruiting | USA | 0 |
NCT02458339 | Phase I | Methotrexate | Methotrexate Infusion Into Fourth Ventricle in Children With Recurrent Malignant Fourth Ventricular Brain Tumors | Completed | USA | 0 |
NCT02472392 | Phase I | Fludarabine Cyclophosphamide Melphalan Busulfan anti-thymocyte globulin | Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma | Completed | USA | 0 |
NCT02502708 | Phase I | Indoximod Temozolomide | Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Primary Malignant Brain Tumors | Completed | USA | 0 |
NCT02644291 | Phase I | Mebendazole | Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | Completed | USA | 0 |
NCT02748135 | Phase Ib/II | TB-403 | A Two-Part Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma | Completed | USA | 0 |
NCT03130959 | Phase II | Ipilimumab + Nivolumab Nivolumab | An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies (CheckMate 908) | Completed | USA | SWE | POL | NOR | NLD | ISR | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 2 |
NCT03155620 | Phase II | Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib | Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) | Recruiting | USA | CAN | AUS | 1 |
NCT03173950 | Phase II | Nivolumab | Immune Checkpoint Inhibitor Nivolumab in People With Select Rare CNS Cancers | Recruiting | USA | 0 |
NCT03213678 | Phase II | LY3023414 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03387020 | Phase I | Ribociclib Everolimus + Ribociclib | Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors | Completed | USA | 0 |
NCT03434262 | Phase I | Ribociclib + Trametinib Filgrastim + Gemcitabine + Ribociclib Ribociclib + Sonidegib | SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors | Completed | USA | 0 |
NCT03581240 | Expanded access | Eflornithine | An Intermediate Expanded Use Trial of DFMO | Available | USA | 0 |
NCT03598244 | Phase I | Savolitinib | Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors | Recruiting | USA | CAN | 0 |
NCT03652545 | Phase I | MultiTAA-specific T cells | Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (REMIND) | Recruiting | USA | 0 |
NCT03698994 | Phase II | Ulixertinib | Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | Active, not recruiting | USA | 1 |
NCT03709680 | Phase I | Irinotecan + Palbociclib + Temozolomide | Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors | Active, not recruiting | USA | TUR | SWE | SVK | POL | NLD | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BGR | BEL | ARG | 2 |
NCT03838042 | Phase Ib/II | Entinostat + Nivolumab | INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt) | Recruiting | SWE | NLD | FRA | DEU | CHE | AUT | AUS | 0 |
NCT03860207 | Phase Ib/II | Hu3F8-BsAb | Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers | Terminated | USA | 0 |
NCT03893487 | Phase I | CUDC-907 | Fimepinostat in Treating Brain Tumors in Children and Young Adults (PNOC016) | Active, not recruiting | USA | CHE | 0 |
NCT03904862 | Phase Ib/II | Silmitasertib | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery | Suspended | USA | 0 |
NCT04023669 | Phase I | Filgrastim Pegfilgrastim Cyclophosphamide + Prexasertib Gemcitabine + Prexasertib | Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors | Active, not recruiting | USA | 0 |
NCT04049669 | Phase II | Cyclophosphamide + Etoposide + Indoximod Indoximod + Lomustine + Temozolomide Indoximod + Temozolomide Indoximod | Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG | Recruiting | USA | 0 |
NCT04315064 | Phase I | MTX110 | Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults With Recurrent Medulloblastoma | Recruiting | USA | 0 |
NCT04334863 | Phase I | WP1066 | AflacST1901: Peds WP1066 | Completed | USA | 0 |
NCT04402073 | Phase II | Cisplatin + Lomustine + Vincristine Sulfate Cisplatin + Lomustine + Sonidegib + Vincristine Sulfate | Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I) | Active, not recruiting | NLD | ITA | FRA | ESP | DEU | CHE | AUT | AUS | 0 |
NCT04541082 | Phase I | ONC206 | Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | Recruiting | USA | 0 |
NCT04743661 | Phase II | Bevacizumab + Irinotecan + Omburtamab I-131 + Temozolomide Omburtamab I-131 | 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma | Active, not recruiting | USA | 0 |
NCT04978727 | Phase I | SurVaxM | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | Recruiting | USA | CAN | 0 |
NCT05064306 | Expanded access | Omburtamab I-131 | 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults | Available | USA | 0 |
NCT05096481 | Phase II | PEP-CMV + Temozolomide | PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | Recruiting | USA | 0 |
NCT05106296 | Phase I | Cyclophosphamide + Etoposide + Ibrutinib + Indoximod | Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer | Recruiting | USA | 0 |
NCT05135975 | Phase II | Cabozantinib | A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors | Recruiting | USA | 0 |
NCT05429502 | Phase Ib/II | Ribociclib + Temozolomide + Topotecan | Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | AUS | 1 |
NCT06161519 | Phase Ib/II | PLX038 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | Recruiting | USA | 0 |
NCT06466798 | Phase I | Methotrexate + Nivolumab Azacitidine + Nivolumab | Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies | Recruiting | USA | 0 |
NCT06624371 | Phase I | Atovaquone | Atovaquone Combined with Radiation in Children with Malignant Brain Tumors (AflacBT2303) | Recruiting | USA | 0 |
NCT06639607 | Phase Ib/II | Nivolumab + PEP-CMV + Temozolomide | PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II) | Not yet recruiting | USA | 0 |